research is rapidly progressing. Advances in basic science and molecular
diagnostics have provided unprecedented possibilities for drug development.

If research
accelerates as expected, by 2025, patient with early symptoms of Alzheimer’s
disease will be treated substantially differently from how they are now. First
they would be seen by their primary care doctor upon first complaints. This
doctor will prescribe risk-factor management and provide personalised advice
for lifestyle modification. The patient will then be referred to a specialist
and undergo MRI scan and undergo amyloid and tau imaging. If the results of
these scans suggest the presence of the disease, the patient might have to be
put on a strict regime of anti-amyloid compounds, anti-tau drugs, synaptic
enhancers, and in serious cases, even gene therapy directed as the progression
to dementia would be monitored. (Scheltens, 2016)Medical imaging will
be used to monitor the treatment in removing amyloid and tau from the brain,
Biomarkers will also be used to monitor the degeneration of the synapses. As a result
of the developments and research of the last few years, such advanced treatment
and management systems are on the way in the near future.

the funding needed to make this a reality is not awarded. Investors and
Governments are more concerned with different fields such as cancer research
and HIV vaccines. These can affect the younger generations and can be far more
progressive than Alzheimer’s but recent studies suggests that people are
beginning to be diagnosed with the disease earlier than ever before. So we can
expect to see giant leaps forward and scientific breakthroughs in Alzheimer’s
research within the next few years.


Scheltens, P., 2016. Alzheimer’
disease. Online
Available at:
Accessed 25 january 2018.